drugset / Trial / NCT04434092

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

NCT04434092

Phase 3 Active not recruiting 210 enrolled Hoffmann-La Roche Chugai Pharmaceutical · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A study designed to evaluate the non-inferiority of crovalimab compared with eculizumab in participants with PNH who have not been previously treated with complement inhibitor therapy.

Timeline

Start
2020-10-08
Primary completion
2022-11-16
Completion
2027-09-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Crovalimab Monoclonal antibody 85 mg Intravenous
Subject Crovalimab Monoclonal antibody 170 mg Intravenous
Subject Crovalimab Monoclonal antibody 340 mg Intravenous
Subject Crovalimab Monoclonal antibody 510 mg Intravenous
Subject Crovalimab Monoclonal antibody 680 mg Intravenous
Subject Crovalimab Monoclonal antibody 1020 mg Intravenous
Comparator Eculizumab Monoclonal antibody 900 mg